Hologic’s AI-powered mammography technology identified a significant number of breast cancer cases that were initially missed during standard screening, according to a new study involving 7,500 screening exams. The research found that the AI system detected approximately one-third of the cancer cases that had been interpreted as negative by radiologists during the initial review. The study highlights the potential of artificial intelligence to enhance early cancer detection and improve diagnostic accuracy in breast cancer screening. Hologic’s AI platform, integrated into its digital mammography systems, analyzes images to flag subtle abnormalities that may be overlooked by human readers, especially in dense breast tissue where early signs of cancer can be difficult to detect. The results are particularly promising for reducing false negatives—cases where cancer is present but not identified during screening—thereby increasing the chances of early intervention and better patient outcomes. The study also suggests that AI can help reduce radiologist workload and improve efficiency, especially in high-volume clinical settings. Hologic, a global leader in women’s health technology, continues to expand its AI capabilities in medical imaging, aiming to support radiologists with decision-making tools that improve both accuracy and consistency. The company emphasized that the AI system is designed to work as a supportive tool, not a replacement, for expert human interpretation. The findings come at a time when the medical community is increasingly turning to AI to address challenges in early disease detection, particularly in areas like breast cancer, where early diagnosis is critical to survival rates. With ongoing research and real-world validation, Hologic’s AI technology may play a growing role in transforming breast cancer screening across healthcare systems worldwide.